Skip to main content

Navigation group

Type at least 3 characters
809 articles

Articles

Clinical Study Protocol

Published on 27 Mar 2019

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

in Neuromuscular Disorders and Peripheral Neuropathies

  • Paul Lingor
  • Markus Weber
  • William Camu
  • Tim Friede
  • Reinhard Hilgers
  • Andreas Leha
  • Christoph Neuwirth
  • René Günther
  • Michael Benatar
  • Magdalena Kuzma-Kozakiewicz
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Frontiers in Neurology
doi 10.3389/fneur.2019.00293
  • 10,414 views
  • 62 citations